The U.S. Food and Drug Administration (FDA) fully approved the first vaccine for active prevention of COVID-19 in individuals 16 years of age and older.
A recent post from a myMatrixx client highlights our ongoing partnership to deliver safe and cost-effective drug therapy through careful prescription monitoring.
myMatrixx Chief Clinical Officer Phil Walls joined John Ruser, PhD, President and CEO of the Workers’ Compensation Research Institute for an on-demand webinar available starting June 24, on the Risk & Insurance website.
The COVID-19 pandemic will continue to have an impact on workers’ compensation pharmacy for the foreseeable future. Recently, myMatrixx Vice President of Business Intelligence, Cliff Belliveau, joined Chief Clinical Officer, Phil Walls, to discuss this new landscape for industry publication Risk & Insurance’s Insights feature.
In a new post for industry publication WorkCompWire, myMatrixx Chief Clinical Officer Phil Walls shares how the COVID-19 pandemic will have a lasting effect on workers’ compensation pharmacy.